SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending as the community discusses recent developments including Gravity SUV deliveries in Canada and a partnership with Riyadh Season. Despite positive news, concerns persist around production targets, potential dilution, and the company's overall financial health, fueling debate among investors. Some are optimistic about Lucid's technology and long-term potential, while others express skepticism about its ability to compete effectively in the EV market.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as traders weigh positive catalysts like potential US-China trade talks against concerns about high valuations and regional banking risks. Community discussions focus on whether the current market action is a bull trap or the start of a sustained rally, with many observing unusual price swings and questioning the influence of algorithmic trading. Some traders are pointing to Trump's comments on China and potential interest rate cuts as bullish signals, while others remain cautious, citing overbought conditions and a potential for a pullback.

Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA.

Artiva Biotherapeutics Inc

ARTV is trending due to positive sentiment around potential upgrades and community excitement about its gains, with some eyeing a move to double digits. Bullish traders are celebrating recent wins and expressing confidence in the stock's undervaluation, citing Wedbush's price target. However, some caution exists regarding potential pullbacks, with a few traders closing positions for profit.

Digital Turbine, Inc. is a mobile growth platform that offers solutions for advertisers, publishers, carriers, and device original equipment manufacturers (OEMs). The firm operates through the On Device Solutions (ODS) and App Growth Platform (AGP) segments. The ODS segment generates revenue from the delivery of mobile application media or content to end users with solutions for all participants in the mobile application ecosystem that want to connect with end users and consumers who hold the device. This includes mobile carriers and device OEMs that participate in the app economy, app publishers and developers, and brands and advertising agencies. The AGP segment provides platforms that allow mobile app publishers and developers to monetize their monthly active users via display, native, and video advertising. The company was founded on November 6, 1998 and is headquartered in Austin, TX.

Digital Turbine Inc

Digital Turbine ($APPS) is trending as investors discuss its potential in the evolving app store landscape following recent rulings and potential AI partnerships; the community is actively debating whether the stock's current momentum is sustainable and if it can maintain its upward trajectory, with some closely watching for a breakout while short positions may get squeezed. Broader discussions cover the company's restructuring, potential acquisitions, and impact of broader market trends.

Firecoin is a digital asset inspired by the concept of the eternal flame, representing energy, resilience, and guidance. It is designed to act as a decentralized token that embodies light and strength, giving holders a sense of empowerment in the digital economy. The project’s purpose is to create a community-driven ecosystem where Firecoin symbolizes progress, illumination, and the ability to move forward regardless of challenges. By leveraging blockchain technology, Firecoin aims to provide transparency, security, and accessibility to its users while maintaining its thematic connection to the symbolic power of fire.

firecoin

$FIRECOIN is experiencing a surge in interest, with community members actively discussing its availability on Phantom Wallet and potential for high gains. The conversation is centered around whether it's a legitimate opportunity or a 'scam,' with some users reporting significant gains while others express skepticism. Many are using Phantom Wallet to monitor activity and track the token's performance relative to other cryptocurrencies like $BTC and $SOL.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X ($CCCX) is trending as the quantum computing sector gains momentum, with community members highlighting its undervaluation compared to peers like $RGTI and potential links to $NVDA. Discussions revolve around the upcoming merger with Infleqtion and its participation in the Q+AI Conference 2025 as potential catalysts. Some investors express excitement about the stock's long-term potential, drawing parallels to past SPAC successes.

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Amstelveen, Netherlands.

ATAI Life Sciences N.V.

ATAI is trending after receiving FDA Breakthrough Therapy Designation for its depression treatment, BPL-003, driving excitement among investors. Community members are discussing Jefferies' raised price target to $10 and the potential for Phase 3 trials, while also weighing the impact of a recent public offering.  The stock is viewed by some as a long-term play in the burgeoning psychedelic medicine sector, drawing comparisons to $TSLA and $NVDA.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health Inc. is trending due to a mix of factors, including recent price volatility and discussions around a potential CEO share sale. The community is debating potential support levels and whether the stock is currently oversold, while also considering the company's broader positioning in the telehealth and pharmaceutical landscape.

VisionWave Holdings, Inc. engages in the forefront of revolutionizing defense capabilities by integrating advanced artificial intelligence (AI) and autonomous solutions across air, ground, and sea domains. The company was founded on September 3, 2024 and is headquartered in Wilmington, DE.

VisionWave Holdings Inc.

VisionWave Holdings, Inc.

VisionWave is trending as traders discuss a potential breakout above the $12.50 resistance, with some pointing to the stock's low float and potential in the AI and defense sectors. Community members are also eyeing call options, anticipating a significant move, while others highlight the company's AI, drone, and sensing technologies, drawing comparisons to $PLTR. Chatter also mentions a recent advisory board formation and successful UAE live-fire trial as potential catalysts.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is trending as traders digest potential shifts in US-China trade relations following comments from former President Trump, contributing to market volatility. Community discussions revolve around identifying key support and resistance levels, with some expressing skepticism about the market's overall strength. Traders are also monitoring the impact of potential bank failures and geopolitical events on the ETF's performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$IOVA BREAKING NEWS!: 1) NCCN Guidelines Jan2025 new update no longer lists progressive disease to start Amtagvi -&gt; this allows pseudo-1L setting use b/c once you give Keytruda, regardless of how a patient responds, you are able to give Amtagvi -- this is kind of already accepting that TILVANCE-301 1L confirmatory trial with interim readout perhaps in 2026 and full approval 2028 is starting to be accounted for by medical experts (NCCN) but more importantly increases TAM significantly right away; 2) REIMBURSEMENT update: company expecting a 9% price increase in reimbursement for Amtagvi and Proleukin in April = that basically accounts for/counters any dilution weighting into stock price -&gt; BUT more importantly, just based on face value, why wouldn&#39;t management increase 2025 Guidance at EO Feb earning correspondingly to $500m+

Zenica

Bobandy

moneybegone

Tralala

Christopher Harvey

CB, Structural Biologist

Stranger

Chiroptera_Capital

lahiyo

thebullofwallst

Clayton Delaney

Jay Huxtable

Giuseppe

smelter

Knish348

Erol

Al R.

Killerpixie

Rose

Obvs Not Telling

Bert Igermann

Quadman5

Norbǝrt Montalǝscot

Idvst8

Kevin Roger

Andrew D

StockTwits Web

Flying Kitty

$IOVA this is phenomenal news…why won’t the company send out a publication!?

StockTwits for iOS

Dave

$IOVA IMO this is some of the most significant news we&#39;ve had in awhile.  I don&#39;t know if it will move the SP, but it should give all the longs a confidence boost.

Iovance Biotherapeutics Inc

 BREAKING NEWS!: 1) NCCN Guidelines Jan2025 new update no longer lists progressive disease to start Amtagvi -> this allows pseudo-1L setting use b/c once you give Keytruda, regardless of how a patient responds, you are able to give Amtagvi -- this is kind of already accepting that TILVANCE-301 1L confirmatory trial with interim readout perhaps in 2026 and full approval 2028 is starting to be accounted for by medical experts (NCCN) but more importantly increases TAM significantly right away; 2) REIMBURSEMENT update: company expecting a 9% price increase in reimbursement for Amtagvi and Proleukin in April = that basically accounts for/counters any dilution weighting into stock price -> BUT more importantly, just based on face value, why wouldn't management increase 2025 Guidance at EO Feb earning correspondingly to $500m+

Bamin

@Bamin and yet no market reaction yet. Crazy

Til Beluga

Bruce Williams

veskin31

@Bamin thanks, great share and this is a very important update. Now, how long before oncologists would be allowed to give patients pembro and TIL? Do they need to wait until approval post TILVANCE? How much of a delay would there be between giving patients pembro and then infusing?

Ned ryerson

Hope

Bluebandito

Aurinia Beach

BroccoliRaab

Michael Doherty

 thanks, great share and this is a very important update. Now, how long before oncologists would be allowed to give patients pembro and TIL? Do they need to wait until approval post TILVANCE? How much of a delay would there be between giving patients pembro and then infusing?

@InvestingSince2021 They can&#39;t give it together til TILVANCE, obviously, but can give Amtagvi earlier now on its own -- should help TAM or at least front-load it for our purposes for coming year you would hope

Rober

Groggok

 They can't give it together til TILVANCE, obviously, but can give Amtagvi earlier now on its own -- should help TAM or at least front-load it for our purposes for coming year you would hope

@Bamin @InvestingSince2021  and thats stage 3 resectable, i think its a full grade better than stage 4 non resectable, which means much healthier latient with better potential outcomes.

Stephen Mikolajczak

  and thats stage 3 resectable, i think its a full grade better than stage 4 non resectable, which means much healthier latient with better potential outcomes.

@Bamin how the guideline change can affect our revenue? Do you see an increase that might happen already this year?

 how the guideline change can affect our revenue? Do you see an increase that might happen already this year?

@Gius_me Yes, more patients will enter TAM at least a little, but see my post on reimbursement by insurance - that is something management needs to address

 Yes, more patients will enter TAM at least a little, but see my post on reimbursement by insurance - that is something management needs to address

@Bamin Great find and reminder to keep track of these guideline updates. However, the updated language still comes under the umbrella of &quot;Recommendations for Patients Who Progress on Systemic Therapy&quot; and so Amtagvi will still be limited to progressive disease it seems. If anything, wording now seems more restrictive as it explicitly specifies &quot;for patients with good performance status.&quot; Inclusion criteria for trial required ECOG 0 or 1 anyway, so not sure why explicit with language now unless they were initially giving to sicker patients post-approval (maybe drop out rates will improve?). Price increase is encouraging but if 2025 guidance already incorporates price increase and mgmt does not increase 2025 guidance during Feb call, stock may be punished further (esp with EU coming online).

Daniel

 Great find and reminder to keep track of these guideline updates. However, the updated language still comes under the umbrella of "Recommendations for Patients Who Progress on Systemic Therapy" and so Amtagvi will still be limited to progressive disease it seems. If anything, wording now seems more restrictive as it explicitly specifies "for patients with good performance status." Inclusion criteria for trial required ECOG 0 or 1 anyway, so not sure why explicit with language now unless they were initially giving to sicker patients post-approval (maybe drop out rates will improve?). Price increase is encouraging but if 2025 guidance already incorporates price increase and mgmt does not increase 2025 guidance during Feb call, stock may be punished further (esp with EU coming online).